Open AccessPostoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
Author(s) -
Zhu Lucheng,
Xia Bing,
Ma Shenglin
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14335
Subject(s) - medicine , radiation therapy , lung cancer , randomized controlled trial , adjuvant radiotherapy , adjuvant , surgery , incidence (geometry) , port (circuit theory) , oncology , physics , electrical engineering , optics , engineering
The role of adjuvant radiotherapy in completely resected pIIIA‐N2 non‐small cell lung cancer (NSCLC) has long been debated. Evidence from previous retrospective and prospective studies showed that postoperative radiotherapy could reduce the incidence of local recurrence and prolong disease‐free survival, while two recently reported randomized controlled trials (lung ART and PORT‐C) both demonstrated no survival benefit of postoperative radiotherapy. The great gap between our knowledge and reality has made us rethink the value of postoperative radiotherapy. In this mini review, we elaborate on the role of postoperative radiotherapy in completely resected pIIIA‐N2 NSCLC.